Alexander E. Filippov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alexander E. Filippov has a total of 73 co-authors. Here are the top co-authors by number of shared publications:
- Andrey G. Obrezan
Saint Petersburg State University
5 shared publications - A. M. Tuktarov
St. Petersburg State University, St. Petersburg
4 shared publications - Albert S. Galyavich
Kazan State Medical University
4 shared publications - Marat V. Ezhov
A.L. Myasnikov Institute of Clinical Cardiology, National Medical Research Center of Cardiology n.a. acad. E.I. Chazov, Ministry of Health of the Russian Federation, Moscow 121552, Russia
4 shared publications - Marina G. Bubnova
National Medical Research Center for Therapy and Preventive Medicine
4 shared publications - Victor S. Gurevich
St. Petersburg State University
4 shared publications
Latest Publications
- Open Access
- 12 October 2026
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 31 (8) , 7114
Metabolic-associated fatty liver disease and hypertriglyceridemia: cardiovascular risks and current therapeutic approaches
Metabolic-associated fatty liver disease (MAFLD) is a systemic disorder associ-ated with metabolic dysfunction and a high risk of life-threatening conditions, primarily cardiovascular disease. MAFLD is often accompanied by hypertriglyceridemia (HTG), as both conditions share a common pathogenetic mechanism — insulin resistance. Both HTG and MAFLD contribute to an increased risk of cardiovascular disease, necessitating personalized HTG treatment algorithms in patients with MAFLD. This paper presents an interdisciplinary expert perspective, summarizing current data on the epidemiology, pathogenesis, clinical features, and management strategies for patients with MAFLD and concomitant HTG. Non-drug approach and pharmacotherapy are discussed, including lifestyle modification, lipid-lowering therapy, and the use of hepatotropic agents. Particular attention is paid to the safety of lipid-lowering therapy. The presented data are based on the results of expert discussion and rationales an early, interdisciplinary, and personalized approach aimed at treating metabolic disorders, reducing cardiovascular risk, and managing liver disease.
- 12 October 2026
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 31 (8) , 7114
Open AccessMetabolic-associated fatty liver disease and hypertriglyceridemia: cardiovascular risks and current therapeutic approaches
Metabolic-associated fatty liver disease (MAFLD) is a systemic disorder associ-ated with metabolic dysfunction and a high risk of life-threatening conditions, primarily cardiovascular disease. MAFLD is often accompanied by hypertriglyceridemia (HTG), as both conditions share a common pathogenetic mechanism — insulin resistance. Both HTG and MAFLD contribute to an increased risk of cardiovascular disease, necessitating personalized HTG treatment algorithms in patients with MAFLD. This paper presents an interdisciplinary expert perspective, summarizing current data on the epidemiology, pathogenesis, clinical features, and management strategies for patients with MAFLD and concomitant HTG. Non-drug approach and pharmacotherapy are discussed, including lifestyle modification, lipid-lowering therapy, and the use of hepatotropic agents. Particular attention is paid to the safety of lipid-lowering therapy. The presented data are based on the results of expert discussion and rationales an early, interdisciplinary, and personalized approach aimed at treating metabolic disorders, reducing cardiovascular risk, and managing liver disease.
- 1 January 2026
- Published by Geotar-Media Publishing Group in Cardiology: News, Opinions, Training
- Vol. 14 (1)
Prognostic value of minor risk factors in the development of atherosclerotic cardiovascular diseases
- 1 January 2026
- Published by Geotar-Media Publishing Group in Cardiology: News, Opinions, Training
- Vol. 14 (1)
Prognostic value of minor risk factors in the development of atherosclerotic cardiovascular diseases
- Open Access
- 27 July 2025
- Published by ECO-Vector LLC in Cardiosomatics
- Vol. 16 (3) , 192-218
Hypertriglyceridemia (triglyceride-rich lipoproteins and their remnants): role in development of atherosclerotic cardiovascular diseases and control strategy consensus statement of the expert Committee of the Russian Society of Cardiology (RSC), the National Atherosclerosis Society (NAS), and the Russian Society of Cardiovascular Prevention and Rehabilitation (RosOKR)
This expert consensus document discusses the high prevalence of cardiovascular diseases (CVDs) caused by atherosclerosis. It is now evident that the causes and pathogenesis of atherosclerotic cardiovascular diseases (ASCVD) cannot always be explained solely by lipid metabolism disorders associated with low-density lipoproteins (LDL). In recent years, an increasing number of studies have focused on hypertriglyceridemia (HTG), including its mechanisms and role in atherothrombogenesis. In this regard, it has become necessary to update key aspects that define the root causes of ASCVD in HTG and the role of triglyceride-rich lipoproteins (TRLs) and their remnants in this process. Epidemiologic and genetic studies have demonstrated a causal relationship between HTG and the development of ASCVD, independent of LDL-C levels. The role of TRLs in determining high residual cardiovascular risk under conditions of LDL-C control has been established, and evidence has been obtained supporting the preventive benefits of lowering elevated plasma triglyceride levels. This document presents the consensus positions of experts regarding the classification, etiology, and mechanisms of HTG, the importance of assessing TRLs/remnants, and a detailed discussion of their metabolism and pathophysiologic role in atherothrombosis. The experts also address the clinical assessment and patient management pathways for HTG, outlining both nonpharmacologic and pharmacologic strategies for its correction.
- 27 July 2025
- Published by ECO-Vector LLC in Cardiosomatics
- Vol. 16 (3) , 192-218
Open AccessHypertriglyceridemia (triglyceride-rich lipoproteins and their remnants): role in development of atherosclerotic cardiovascular diseases and control strategy consensus statement of the expert Committee of the Russian Society of Cardiology (RSC), the National Atherosclerosis Society (NAS), and the Russian Society of Cardiovascular Prevention and Rehabilitation (RosOKR)
This expert consensus document discusses the high prevalence of cardiovascular diseases (CVDs) caused by atherosclerosis. It is now evident that the causes and pathogenesis of atherosclerotic cardiovascular diseases (ASCVD) cannot always be explained solely by lipid metabolism disorders associated with low-density lipoproteins (LDL). In recent years, an increasing number of studies have focused on hypertriglyceridemia (HTG), including its mechanisms and role in atherothrombogenesis. In this regard, it has become necessary to update key aspects that define the root causes of ASCVD in HTG and the role of triglyceride-rich lipoproteins (TRLs) and their remnants in this process. Epidemiologic and genetic studies have demonstrated a causal relationship between HTG and the development of ASCVD, independent of LDL-C levels. The role of TRLs in determining high residual cardiovascular risk under conditions of LDL-C control has been established, and evidence has been obtained supporting the preventive benefits of lowering elevated plasma triglyceride levels. This document presents the consensus positions of experts regarding the classification, etiology, and mechanisms of HTG, the importance of assessing TRLs/remnants, and a detailed discussion of their metabolism and pathophysiologic role in atherothrombosis. The experts also address the clinical assessment and patient management pathways for HTG, outlining both nonpharmacologic and pharmacologic strategies for its correction.
- Open Access
- 2 June 2025
- Published by Intermedservice Ltd in Eurasian heart journal
- No. 2,p. 6-34
Eurasian Association of Cardiology (EAC)/ Russian National Atherosclerosis Society (RNAS) Guidelines for the diagnosis and correction of dyslipidemia for the prevention and treatment of atherosclerosis (2025)
Cardiovascular diseases are one of the main causes of mortality and disability among the population of the member countries of the Eurasian Association of Cardiology, which is directly related to the high prevalence of risk factors for atherosclerosis, among which dyslipidemia plays a leading role. The previous version of the Eurasian Recommendations for the Diagnosis and correction of lipid metabolism disorders for the prevention and treatment of atherosclerosis was presented in 2020. Over the past 5 years, approaches to risk stratification, diagnosis of subclinical atherosclerosis, and correction of dyslipidemia using various classes of lipid-lowering drugs have changed significantly. Among the initial updates, proposals should be highlighted for determining the blood lipid level in each adult or upon reaching the age of 18, using the SCORE and/or SCORE2 scales to stratify cardiovascular risk, and non-invasive imaging techniques to assess subclinical atherosclerosis. In the sections devoted to therapy, fixed combinations of lipid-lowering drugs, inclisiran, and bempedoic acid are presented. The section on the prevalence, significance and approaches to correction of hypertriglyceridemia, as well as the section on extracorporeal hemocorrection, has been expanded. A chapter on lipoprotein(a) is introduced. Sections on correction of dyslipidemia in cerebrovascular diseases, heart transplantation and HIV infection are presented. These recommendations will be useful to the phisicians of all specialties for the effective management of their patients.
- 2 June 2025
- Published by Intermedservice Ltd in Eurasian heart journal
- No. 2,p. 6-34
Open AccessEurasian Association of Cardiology (EAC)/ Russian National Atherosclerosis Society (RNAS) Guidelines for the diagnosis and correction of dyslipidemia for the prevention and treatment of atherosclerosis (2025)
Cardiovascular diseases are one of the main causes of mortality and disability among the population of the member countries of the Eurasian Association of Cardiology, which is directly related to the high prevalence of risk factors for atherosclerosis, among which dyslipidemia plays a leading role. The previous version of the Eurasian Recommendations for the Diagnosis and correction of lipid metabolism disorders for the prevention and treatment of atherosclerosis was presented in 2020. Over the past 5 years, approaches to risk stratification, diagnosis of subclinical atherosclerosis, and correction of dyslipidemia using various classes of lipid-lowering drugs have changed significantly. Among the initial updates, proposals should be highlighted for determining the blood lipid level in each adult or upon reaching the age of 18, using the SCORE and/or SCORE2 scales to stratify cardiovascular risk, and non-invasive imaging techniques to assess subclinical atherosclerosis. In the sections devoted to therapy, fixed combinations of lipid-lowering drugs, inclisiran, and bempedoic acid are presented. The section on the prevalence, significance and approaches to correction of hypertriglyceridemia, as well as the section on extracorporeal hemocorrection, has been expanded. A chapter on lipoprotein(a) is introduced. Sections on correction of dyslipidemia in cerebrovascular diseases, heart transplantation and HIV infection are presented. These recommendations will be useful to the phisicians of all specialties for the effective management of their patients.
- Open Access
- 15 March 2025
- Published by ECO-Vector LLC in Cardiosomatics
- Vol. 16 (1) , 5-20
The place of original pitavastatin in primary and secondary prevention of cardiovascular diseases. Interdisciplinary Expert Consensus of the Russian Society of Cardiology, the National Atherosclerosis Society, the Russian Society of Cardiosomatic Rehabilitation and Secondary Prevention, and the Russian Association of Endocrinologists
The presented expert paper discusses the high prevalence of hypercholesterolemia (HCH) in Russia. Insufficient use of lipid-lowering therapy in both primary and secondary prevention is indicated. Failure to achieve the target level of low-density lipoprotein cholesterol (HC) and low adherence (especially long-term) of patients to hypolipidemic drugs remains a serious problem in real clinical practice. Statins are a class of widely prescribed lipid-lowering drugs that are the first choice drugs in the treatment of HCV and combined hyperlipidemia (GLP) with proven efficacy in the prevention of atherosclerotic cardiovascular diseases. Using the example of the original pitavastatin, this expert document convincingly demonstrates the drug's capabilities not only in reducing atherogenic lipids and lipoproteins in blood plasma, but also its clinical effectiveness in the primary and secondary prevention of cardiovascular complications. This highlights the unique effect of pitavastatin on increasing low cholesterol levels of high-density lipoproteins, proven anti-atherosclerotic activity and a wide range of positive pleiotropic effects that enhance its antiatherogenic effect. The low risk of drug interactions inherent in pitavastatin highlights its high safety with prolonged use and good tolerability. All of the above gives grounds to consider the original pitavastatin as the drug of choice for a wide range of patients. This article was previously published in: Bubnova MG, Galyavich AS, Ezhov MV, Aronov DM, Vinogradova NN, Galstyan GR, Gurevich VS, Karpov YuA, Koziolova NA, Kosmacheva ED, Matyushin GV, Sergienko IV, Filippov AE, Khalimov YuSh. The place of original pitavastatin in primary and secondary prevention of cardiovascular diseases. Interdisciplinary Expert Consensus of the Russian Society of Cardiology, the National Atherosclerosis Society, the Russian Society of Cardiosomatic Rehabilitation and Secondary Prevention, and the Russian Association of Endocrinologists. Russian Journal of Cardiology. 2024;29(11):6148. doi: 10.15829/1560-4071-2024-6148. EDN: PSIJPF The article was published with the consent of the author's team and the editorial board of the Russian Journal of Cardiology and does not contradict the Creative Commons Attribution 4.0 License.
- 15 March 2025
- Published by ECO-Vector LLC in Cardiosomatics
- Vol. 16 (1) , 5-20
Open AccessThe place of original pitavastatin in primary and secondary prevention of cardiovascular diseases. Interdisciplinary Expert Consensus of the Russian Society of Cardiology, the National Atherosclerosis Society, the Russian Society of Cardiosomatic Rehabilitation and Secondary Prevention, and the Russian Association of Endocrinologists
The presented expert paper discusses the high prevalence of hypercholesterolemia (HCH) in Russia. Insufficient use of lipid-lowering therapy in both primary and secondary prevention is indicated. Failure to achieve the target level of low-density lipoprotein cholesterol (HC) and low adherence (especially long-term) of patients to hypolipidemic drugs remains a serious problem in real clinical practice. Statins are a class of widely prescribed lipid-lowering drugs that are the first choice drugs in the treatment of HCV and combined hyperlipidemia (GLP) with proven efficacy in the prevention of atherosclerotic cardiovascular diseases. Using the example of the original pitavastatin, this expert document convincingly demonstrates the drug's capabilities not only in reducing atherogenic lipids and lipoproteins in blood plasma, but also its clinical effectiveness in the primary and secondary prevention of cardiovascular complications. This highlights the unique effect of pitavastatin on increasing low cholesterol levels of high-density lipoproteins, proven anti-atherosclerotic activity and a wide range of positive pleiotropic effects that enhance its antiatherogenic effect. The low risk of drug interactions inherent in pitavastatin highlights its high safety with prolonged use and good tolerability. All of the above gives grounds to consider the original pitavastatin as the drug of choice for a wide range of patients. This article was previously published in: Bubnova MG, Galyavich AS, Ezhov MV, Aronov DM, Vinogradova NN, Galstyan GR, Gurevich VS, Karpov YuA, Koziolova NA, Kosmacheva ED, Matyushin GV, Sergienko IV, Filippov AE, Khalimov YuSh. The place of original pitavastatin in primary and secondary prevention of cardiovascular diseases. Interdisciplinary Expert Consensus of the Russian Society of Cardiology, the National Atherosclerosis Society, the Russian Society of Cardiosomatic Rehabilitation and Secondary Prevention, and the Russian Association of Endocrinologists. Russian Journal of Cardiology. 2024;29(11):6148. doi: 10.15829/1560-4071-2024-6148. EDN: PSIJPF The article was published with the consent of the author's team and the editorial board of the Russian Journal of Cardiology and does not contradict the Creative Commons Attribution 4.0 License.
- Open Access
- 18 October 2024
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 29 (11) , 6148
Interdisciplinary Expert Consensus: the place of original pitavastatin in primary and secondary prevention of cardiovascular diseases
Russian Society of Cardiology, National Atherosclerosis Society, Russian Society of Cardiosomatic Rehabilitation and Secondary Prevention, Russian Association of Endocrinologists
- 18 October 2024
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 29 (11) , 6148
Open AccessInterdisciplinary Expert Consensus: the place of original pitavastatin in primary and secondary prevention of cardiovascular diseases
Russian Society of Cardiology, National Atherosclerosis Society, Russian Society of Cardiosomatic Rehabilitation and Secondary Prevention, Russian Association of Endocrinologists
- 1 January 2023
- Published by Geotar-Media Publishing Group in Cardiology: News, Opinions, Training
- Vol. 11 (1)
Irrational nutrition and chronic stress – are the key causes of cardiovascular diseases and premature aging of a person?
Нерациональное питание и хронический стресс - ключевые причины возникновения сердечно-сосудистых заболеваний и преждевременного старения человека?
- 1 January 2023
- Published by Geotar-Media Publishing Group in Cardiology: News, Opinions, Training
- Vol. 11 (1)
Irrational nutrition and chronic stress – are the key causes of cardiovascular diseases and premature aging of a person?
Нерациональное питание и хронический стресс - ключевые причины возникновения сердечно-сосудистых заболеваний и преждевременного старения человека?
- 1 January 2022
- Published by Geotar-Media Publishing Group in Cardiology: News, Opinions, Training
- Vol. 10 (2)
Smoking status and its relationship with early vascular aging
Статус курения и его взаимосвязь с ранним сосудистым старением
- 1 January 2022
- Published by Geotar-Media Publishing Group in Cardiology: News, Opinions, Training
- Vol. 10 (2)
Smoking status and its relationship with early vascular aging
Статус курения и его взаимосвязь с ранним сосудистым старением
- Open Access
- 3 March 2021
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 17 (1) , 42-48
The Relationship of Modifiable Risk Factors with Indicators of Arterial Stiffness and Vascular Age in Patients with Arterial Hypertension
Aim. To study the relationship of modifiable risk factors (RF) with indicators of arterial stiffness and vascular age based on the contour analysis of the pulse wave velocity in hypertensive patients.Material and methods. The material of the study was the data from a survey of patients undergoing clinical observation at the polyclinic of MMC SOGAZ. A total of 107 patients were examined, in which 70 were men and 37 were women. The average age was 52.3±18.29. Photoplethysmography was used as a special research method, performed using the AngioScan-01 diagnostic complex. The main indicators used to evaluate the stiffness of large vessels were: stiffness index (SI), reflection index (RI), augmentation index (Alp75), age index (AGI), pulse wave types (PV) and vascular age (VA).Results. The mean values of arterial stiffness indices in patients with essential arterial hypertension (AH) and healthy individuals (control) had significant differences. The mean SI, Alp75, and VA values in the group of patients with AH were 7.8±1.03, 7.0±14.44 and 50.8±15.93 versus 7.2±1.73, 0.5±18.02 and 43.8±16.94, respectively (p< 0.05). In both groups, a strong inverse correlation of passport age with C-type PV was revealed (r=0.74, p< 0.01), which reflected the dynamics of a gradual age-dependent decrease in vascular compliance. The average VA value in the control group was 63.1±16.99 years with an average passport age of 59.5±8.79 years, which significantly differed from VA in hypertensive patients (p< 0,05). Overweight, hypercholesterolemia, elevated low-density lipoprotein levels, lack of adequate antihypertensive control, and left ventricular diastolic dysfunction were significantly associated with early vascular (arterial) aging.Conclusion. Patients with hypertension, in addition to high blood pressure, significantly differ from normotensive control in terms of arterial stiffness. The lack of control over modifiable RF of patients with hypertension is associated with early vascular aging.
- 3 March 2021
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 17 (1) , 42-48
Open AccessThe Relationship of Modifiable Risk Factors with Indicators of Arterial Stiffness and Vascular Age in Patients with Arterial Hypertension
Aim. To study the relationship of modifiable risk factors (RF) with indicators of arterial stiffness and vascular age based on the contour analysis of the pulse wave velocity in hypertensive patients.Material and methods. The material of the study was the data from a survey of patients undergoing clinical observation at the polyclinic of MMC SOGAZ. A total of 107 patients were examined, in which 70 were men and 37 were women. The average age was 52.3±18.29. Photoplethysmography was used as a special research method, performed using the AngioScan-01 diagnostic complex. The main indicators used to evaluate the stiffness of large vessels were: stiffness index (SI), reflection index (RI), augmentation index (Alp75), age index (AGI), pulse wave types (PV) and vascular age (VA).Results. The mean values of arterial stiffness indices in patients with essential arterial hypertension (AH) and healthy individuals (control) had significant differences. The mean SI, Alp75, and VA values in the group of patients with AH were 7.8±1.03, 7.0±14.44 and 50.8±15.93 versus 7.2±1.73, 0.5±18.02 and 43.8±16.94, respectively (p< 0.05). In both groups, a strong inverse correlation of passport age with C-type PV was revealed (r=0.74, p< 0.01), which reflected the dynamics of a gradual age-dependent decrease in vascular compliance. The average VA value in the control group was 63.1±16.99 years with an average passport age of 59.5±8.79 years, which significantly differed from VA in hypertensive patients (p< 0,05). Overweight, hypercholesterolemia, elevated low-density lipoprotein levels, lack of adequate antihypertensive control, and left ventricular diastolic dysfunction were significantly associated with early vascular (arterial) aging.Conclusion. Patients with hypertension, in addition to high blood pressure, significantly differ from normotensive control in terms of arterial stiffness. The lack of control over modifiable RF of patients with hypertension is associated with early vascular aging.